Conclusions:
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Objectives: To compare the efficacy of TCZ-SC with PBO or TCZ-IV + csDMARDs for improvement in patient-reported outcomes (PROs) in 2 RCT populations. Methods: Both RCTs enrolled patients (pts) with inadequate responses to DMARDs; up to 20% had inadequate responses to tumor necrosis factor inhibitors. In BREVACTA, pts received blinded TCZ-SC 162 mg or PBO every 2 weeks (q2w) + csDMARDs for 24 weeks. In SUMMACTA, pts received TCZ-SC 162 mg weekly or TCZ-IV 8 mg/kg q4w + csDMARDs for the 24-week double-blind period. PROs, assessed at 12 weeks (prior to rescue) in BREVACTA and 24 weeks in SUMMACTA, included patient global assessment (PtGA; visual analog score [VAS], 0-100 mm), pain (VAS), Health Assessment Questionnaire Disability Index (HAQ-DI, 0-3) and Short Form-36 (SF-36) physical and mental component summary (PCS, MCS: 0-50) and domain (0-100) scores. The proportions of pts reporting scores ≥ minimum clinically important differences (MCID) and ≥ age/gender-matched normative values were assessed for each treatment group. Results: Baseline PRO scores were mostly comparable between treatment groups in each study and between study populations. In BREVACTA, significantly more pts who received TCZ-SC reported scores ≥ MCID for all PROs at week 12 compared with PBO (54% to 73% vs 42% to 55%, respectively; number needed to treat [NNT], 5.2 to 13.0). Compared with 1% to 20% at baseline, 8% to 34% of pts who received TCZ-SC and 4% to 25% of PBO pts reported scores ≥ normative values in all PROs at week 12 (Table) . In SUMMACTA, similar proportions of pts who received TCZ-SC and TCZ-IV reported scores ≥ MCID in all PROs at week 24 (61% to 84% vs 64% to 84%, respectively). The proportion of patients who reported scores ≥ normative values was comparable between the TCZ-SC and TCZ-IV groups across all PROs; compared with 0.2% to 23% at baseline, 14% to 41% of pts who received TCZ-SC and 15% to 42% of pts who received TCZ-IV reported scores ≥ normative values at week 24 (Table) .
Conclusions:
In BREVACTA, TCZ-SC + csDMARDs resulted in significantly greater improvements across all PROs and significantly more pts reporting scores ≥ MCID at week 12 compared with PBO. Similarly, more pts receiving TCZ-SC reported scores ≥ normative values at week 12 compared with PBO, despite few pts with such scores at baseline. Responses were similar between pts treated with TCZ-SC and TCZ-IV + csDMARDs in SUMMACTA at week 24. These data show TCZ treatment resulted in clinically meaningful improvements in PROs and indicate that attainment of normative scores is a realistic goal in treatment of pts with active RA. Background: Cervical lesions are known to occur at high frequency as a complication of rheumatoid arthritis (RA). Treatment with biological agents are more clinically effective than the DMARDs that were in use previously, in particular, with their efficacy in suppressing joint destruction having been emphasized. We reported the efficacy of infliximab, anti-tumor necrosis factor antibodies for suppressing the radiographic progression of RA cervical lesions at ACR2009, EULAR2010, 11, 12, 13, 14 and 16. However there is still few studies of efficacy of against RA cervical lesions of Tocilizumab (TCZ), anti-interleukin 6 receptor antibody. Objectives: To evaluate the efficacy of TCZ for suppressing the radiographic progression of RA cervical lesions comparison with MTX for 2 years. Methods: We used TCZ or MTX for treating Japanese patients with active RA who fulfilled the ACR criteria in 1987. The final study cohort of each 38 and 71 patients received continuous TCZ and MTX treatment for at least 2 years. For evaluation of cervical lesions, the atlanto-dental interval (ADI), the space available for the spinal cord (SAC), and the Ranawat value were measured by plain lateral radiographs in the flexion position, at initiation and Year 1,2. Results: In the patients receiving TCZ (n=38) and MTX (n=71), the number of female were each 28 (72%) and 51 (72%) cases (p=0.999). The mean age was 57.3±12.4 and 63.3±10.9 years old (p=0.011); disease duration was 7.0±7.3 and 8.8±9.7 years (p=0.929) and the mean dose of MTX was 9.0±3.4 and 8.3±2.9 mg/w (p=0.335). Clinical findings related to RA were as follows; CRP 3.8±3.1 and 1.5±2.1 mg/dl (p<0.001); ESR 52.7±25.3 and 30.0±20.8mm/h (p<0.001); MMP3 400±300 and 213±356ng/ml (p<0.001); the number of RF-positive 30 (79%) and 58 (82%) (Fig.1) . The numbers of patients who did not showed progression in ADI, SAC and Ranawat value were each 30 (79%) and 41 (58%) cases (p=0.035); 30 (79%) and 44 (62%) cases (p=0.087) and 30 (79%) and 49 (69%) cases (p=0.367) after 2 years. Also the number who was able to suppress progression in all three parameters were each 29 cases (76%) receiving TCZ and 41 cases (58%) receiving MTX (p=0.062) after 2 years (Fig.2) Background: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by fluctuating disease activity in which adverse long-term outcomes remain a major challenge. In the face of extreme individual unpredictability of the disease course over time, four different patterns can be defined, as elsewhere described [1], using SLEDAI-2K (Systemic Lupus Erythematosus Disease Activity Index-2K) excluding serology in order to focus on clinical activity. The patterns are clinical quiescent disease (CQD), chronic active disease (CAD), relapsing-remitting disease (RRD) and minimal disease activity (MDA). Objectives: The aim of our study was to assess the association between different disease activity patterns and damage accrual in SLE patients. Methods: Patients with SLE registered at our Lupus Clinic at the Rheumatology Unit, between 1 January 2013 and 1 October 2016, were included. Demographic and clinical variables included age, gender, age at SLE onset, major organ involvement. SDI (Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index) was categorized as absent (SDI=0) or present (SDI ≥1), Disease activity patterns (CQD, MDA, RRD, CAD) were retrospectively assessed. Drugs used in the treatment of SLE, including hydroxychloroquine, cumulative dose of glucocorticoid (prednisone equivalent >10 g) and other immunosuppressive drugs, were also collected. Multivariate logistic regression analyses were performed to identify disease patterns associated with damage accrual. Results are presented as odds ratio (OR) and 95% confidence intervals (CI). Results: A total of 473 Caucasian patients were observed, mainly female (89.4% F, 10.6% M), mean age 52.6 years (± 14.9 SD). In our cohort, the disease activity pattern distribution was as follows: 65.4% CQD (290 pts), 21.5% RRD (91 pts), 6.1% MDA (28 pts) and CAD in 19.1% of the cases (64 pts). Damage was significantly more frequent in CAD subset (81.2%, 52/64 pts) versus 54.5% in CQD (158/290 pts), 50% in MDA (14/28 pts) and 58.2% in RRD (53/91 pts). Compared to a CQD course, CAD pattern was independently associated with overall damage after controlling for factors including gender, disease duration, cumulative glucocorticoid dosage, major individual organ involvement (neuropsychiatric and renal), positive antiphospholipid antibody profile, exposures to cyclophosphamide and hydroxychloroquine (Table 1) .
